AstraZeneca cans late-stage Ultomiris trial on lacklustre efficacy predictions
AstraZeneca halted the Phase III AWAKE trial for Ultomiris in kidney transplant patients due to predicted lack of efficacy, despite the drug's safety. The decision came from an independent data monitoring committee. Ultomiris remains approved for five rare disease indications and generated $1.4bn in Q3 revenue, up 17% year-over-year. Analysts project $6.3bn in sales by 2032.
How this was made
The 30-second read
Why it matters
The failure to meet the primary endpoint may reduce near‑term revenue expectations and weigh on the stock, though safety data remain encouraging.
Market read
First‑report trial termination provides fresh material for traders; likely short‑term downside for AZN.
What to watch
The trial's safety data were positive, and the drug still drives significant revenue growth.
Background
AstraZeneca announced the termination of its late‑stage AWAKE trial for Ultomiris, a C5 inhibitor used in rare‑disease treatments.
Ticker impact
AstraZeneca terminated the Phase III AWAKE trial for Ultomiris after data showed unlikely to meet primary endpoint.
likely downside as market prices in the failed trial
The primary endpoint miss is a material negative catalyst for a major revenue driver.
Market effects
Highlights risk in rare‑disease biotech pipelines and may pressure peer companies with similar C5 inhibitors.
Potential sell pressure on UK and US pharma stocks following the news.
Adds caution to global investors tracking pharma R&D outcomes.
Counterpoint
Despite the setback, Ultomiris remains safe and could succeed in other indications, supporting a longer‑term view.
Key entities
- companyAstraZeneca
Global pharmaceutical company conducting the trial.
- drugUltomiris (ravulizumab)
C5 inhibitor under investigation for delayed graft function.
